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This study aimed to determine the incidence and characteristics of active tuberculosis (TB) in patients 
treated with tumor necrosis factor (TNF) antagonists according to baseline latent tuberculosis infection 
(LTBI). Data were retrospectively obtained from 702 patients aged ≥20 years treated with TNF 
antagonists between November 2005 and June 2016 at Severance Hospital, a tertiary referral hospital 
in Seoul, South Korea. The interferon-gamma release assay (IGRA) with or without a tuberculin skin 
test (TST) was used to diagnose LTBI. Of the total of 702 patients, LTBI was diagnosed in 255 (36.3%) 
patients. 23.9% (168/702) had positive IGRA results, and 32.2% (165/512) had positive TST results. Five 
patients developed active TB after LTBI treatment, and 6 developed TB despite baseline negative LTBI 
results. After adjustment for age and sex, the standardized TB incidence ratio was 6.01 (95% CI 1.94–
14.04) in the LTBI group and 5.14 (95% CI 1.88–11.18) in the baseline negative LTBI group. Clinicians 
should be aware of the risk of active TB in patients treated with TNF antagonists despite baseline 
negative LTBI screening results. Regular monitoring and serial tests should be considered during long-
term TNF antagonist therapy, especially in intermediate to high TB burden country.
Tumor necrosis factor (TNF) and TNF receptors play important roles in mediating the immune system and 
inflammatory systems. Recently, TNF antagonists have been increasingly used in the treatment of chronic inflam-
matory diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis, and inflammatory 
bowel disease. Despite the effectiveness of TNF antagonist treatment, one of the most serious side effects is an 
associated increased risk of developing tuberculosis (TB), mostly through reactivation of latent tuberculosis 
infection (LTBI)1–3. Most guidelines suggest that LTBI should be screened for before the initiation of TNF antag-
onist therapy, and recommend LTBI treatment2, 4–7. However, screening strategies and treatment regimens differ 
between countries. Despite rapid economic growth and urbanization, South Korea has been ranked as having 
the highest incidence and prevalence of TB among Organization for Economic Cooperation and Development 
(OECD) member countries. The annual incidence of notified active TB cases is approximately 78 per 100,000 in 
the general population in 2011, and the estimated prevalence of latent TB is 33%8, 9. Therefore, the risk of develop-
ing TB through LTBI reactivation or a new infection in patients undergoing TNF antagonist therapy in Korea is 
reportedly higher than it is in countries with a low TB burden10, 11. Studies investigating the incidence and charac-
teristics of active TB in patients undergoing TNF antagonist therapy according to baseline LTBI are important in 
countries with a relatively high TB burden. In this study, we evaluated baseline LTBI screening results in patients 
treated with TNF antagonists in a 2000-bed tertiary referral hospital in Seoul, South Korea, and determined the 
incidence and characteristics of active TB according to baseline LTBI status.
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Patients and Methods
Study population. A total of 823 patients treated with TNF antagonists between November 2005 and June 
2016 at Severance Hospital, a 2000-bed tertiary referral hospital in Seoul, South Korea were analyzed. Medical 
records were retrospectively reviewed. Patients who were under 20 years of age (n = 55), only used TNF antago-
nists once (n = 18), were not properly screened for LTBI before TNF antagonist therapy (n = 15), and those with 
a history of active TB who had had proper anti-TB treatment (n = 32) or an active tuberculosis diagnosis at the 
time of TNF antagonist initiation (n = 1) were excluded (Fig. 1).
Diagnosis and treatment of LTBI. The interferon gamma (IFN-ɣ) release assay (IGRA) using 
QuantiFERON® TB-Gold In Tube (QFT-GIT) with or without a tuberculin skin test (TST) was performed in 
a total of 702 patients to screen for LTBI before TNF antagonist therapy in accordance with the Korean guide-
lines4. Chest radiographs and symptoms were evaluated to exclude active TB. The QFT-GIT was performed 
in accordance with the manufacturer’s instructions (Cellestis Ltd., Carnegie, Victoria, Australia). A positive 
QFT-GIT result was defined as an IFN-ɣ response to TB antigen minus that of the nil tube of ≥0.35 IU/mL. The 
TST was performed in 515 patients. A 2-TU dose of purified protein derivative RT-23 (Statens Serum Institute, 
Copenhagen, Denmark) was injected intradermally into the forearm, in accordance with the Mantoux method12. 
A positive TST result was defined as an induration 10 mm in transverse diameter after 48–72 h4. Where IGRA 
or TST results were positive, patients were diagnosed as LTBI and patients were treated with either 9 months of 
daily isoniazid (9H) or 3 months of daily isoniazid plus rifampicin (3HR) according to the treating physician’s 
preference. Treatment completion was defined as the ingestion of >80% of all prescribed medications within 43 
weeks for 9H or within 16 weeks for 3HR13. Previous healed TB in chest radiography was defined by the presence 
of apical fibronodular lesions, calcified lymph nodes, calcified solitary nodules, and pleural thickening14.
Follow-up. Follow-up duration was calculated until the development of active TB, death, or transfer to 
another hospital. Otherwise, patients were observed until September 2016, with a focus on active TB develop-
ment after TNF antagonist therapy.
Calculation of TB incidence. Standardized incidence ratio (SIR) adjusted for age and sex was estimated 
using data from the general population of Korea, obtained from the Korean National Statistics Office15. The SIR 
was calculated as the ratio of the observed number of active TB cases among patients receiving TNF antagonists 
to the expected number of active TB cases with a 95% confidence interval (CI). The expected number of active 
TB cases treated with TNF antagonists was extrapolated from the active TB incidence in the general popula-
tion in 2011 (the midpoint of 2005–2016), which was provided by the Korean Centers for Disease Control and 
Prevention9.
Statistical analysis. Continuous data were expressed as mean ± SD or median and range. Percentages and 
frequencies were used for categorical variables. Categorical variables were compared using chi-square tests or 
Figure 1. LTBI screening and active TB development in patients treated with TNF antagonists. TNF, tumor 
necrosis factor; TB, tuberculosis; LTBI, latent tuberculosis infection; IGRA, interferon-gamma release assay; 
TST, tuberculin skin test; ND, not done.
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Fisher’s exact test, and Student’s t-tests were performed for continuous variables. p values < 0.05 were considered 
significant. All statistical analyses were performed using SPSS version 18.0 (SPSS Inc. Chicago, IL, USA).
Ethics. The research protocol was approved by the Institutional Review Board (IRB) of Severance Hospital 
(IRB No. 4-2016-0989). The need for informed consent was waived due to the retrospective nature of the study.
Results
Baseline characteristics. Table 1 shows the clinical characteristics of patients treated with TNF antagonists. 
Of the total of 702 patients, 255 were diagnosed with LTBI (the LTBI group) before TNF antagonist use, and 447 
tested negative for LTBI (the no-LTBI group). The median age of the 702 patients was 44 years (range 20–84) and 
the LTBI group was significantly older than no-LTBI group (mean 50 years vs. mean 39 years, P < 0.001). There 
were 356 (50.7%) male patients.
Eleven patients exhibited healed TB lesions on chest radiographs before TNF antagonist use despite having 
no history of TB treatment. Of these, 2 had negative LTBI screening results and did not receive LTBI treatment, 
Characteristic LTBI (n = 255)
No LTBI 
(n = 447) Total (n = 702) P
Age, years, median (range) 50 (21–78) 39 (20–84) 44 (20–84) <0.001
Sex (male), n (%) 134 (52.5) 222 (49.7) 356 (50.7) 0.462
BMI, mean ± SD, kg/m2 22.83 ± 3.41 21.76 ± 3.93 22.19 ± 3.76 <0.001
Chest x-ray finding suggestive 
healed TB, n (%) 9 (3.5) 2 (0.4) 11 (1.6) 0.003*
Main diagnosis, n(%)
 Rheumatoid arthritis 119 (46.7) 140 (31.3) 259 (36.9) <0.001
 Ankylosing spondylitis 81 (31.8) 93 (20.8) 174 (24.8) 0.001
 Crohn’s disease 16 (6.3) 125 (28.0) 141 (20.1) <0.001
 Ulcerative colitis 24 (9.4) 56 (12.5) 80 (11.4) 0.211
 Others 15 (5.9) 33 (7.4) 48 (6.8) 0.449
Comorbidity, n (%)
 HTN 30 (11.8) 46 (10.3) 76 (10.8) 0.546
 DM 19 (7.5) 19 (4.3) 38 (5.4) 0.072
 Chronic lung disease† 3 (1.2) 10 (2.2) 13 (1.9) 0.394*
 Chronic kidney disease 6 (2.4) 6 (1.3) 12 (1.7) 0.369*
 Chronic liver disease 3 (1.2) 5 (1.1) 8 (1.1) 1.000*
 Malignancy 10 (3.9) 10 (2.2) 20 (2.8) 0.197
TNF antagonist, n (%)
 Infliximab 47 (18.4) 161 (36.0) 208 (29.6) <0.001
 Adalimumab 57 (22.4) 139 (31.1) 196 (27.9) 0.013
 Golimumab 20 (7.8) 31 (6.9) 51 (7.3) 0.656
 Etanercept 48 (18.8) 34 (7.6) 82 (11.7) <0.001
 Two or more TNF antagonists 83 (32.5) 82 (18.3) 165 (23.5) <0.001
Immunosuppressive drugs, n (%)
 Steroid 146 (57.3) 201 (45.0) 347 (49.4) 0.002
 Antimetabolite‡ 149 (58.4) 292 (65.3) 441 (62.8) 0.069
 Calcineurin inhibitor§ 13 (5.1) 7 (1.6) 20 (2.8) 0.007
 Combination 172 (67.5) 309 (69.1) 481 (68.5) 0.646
 Other DMARDs¶ 136 (53.3) 274 (61.3) 410 (58.4) 0.039
 None 5 (2.0) 19 (4.3) 24 (3.4) 0.108
Duration of TNF antagonist use, 
median (range), months 18.6 (0.5–114.8) 12.7 (0.5–108.7) 15.5 (0.5–114.8) 0.002
Duration of follow up, median 
(range), months 32.6 (1.1–131.3) 31.8 (0.5–126.7) 32.1 (0.5–131.3) 0.007
Results of LTBI test
 TST induration (mm; median, IQR) 12 (8.75–15) 0 (0–0) 0 (0–11) <0.001
 IFN- γ concentration (IU/
mL;median, IQR) 0.74 (0.08–2.97) 0.01 (0–0.04) 0.02 (0–0.29) <0.001
Table 1. Baseline characteristics of patients who were treated with TNF antagonists. Data are presented 
as numbers (percentages) unless otherwise indicated. *Compared using Fisher’s exact test. †Chronic 
obstructive pulmonary disease, asthma, bronchiectasis, interstitial lung disease. ‡Methotrexate, Azathioprine. 
§Cyclosporine, Tacrolimus. ¶5-Amino salicylic acid derivative, Leflunomide. LTBI, latent tuberculosis infection; 
BMI, body mass index; TB, tuberculosis; HTN, hypertension; DM, diabetes mellitus; TNF, tumor necrosis 
factor; DMARD, disease modifying anti-rheumatic drugs.
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although most guidelines recommend LTBI treatment in such patients4–6, 16. The most frequent disease requiring 
TNF antagonist therapy was RA (36.9%), followed by AS (24.8%), Crohn’s disease (CD) (20.1%), ulcerative colitis 
(UC) (11.4%), and “others” (6.8%). The LTBI group had more RA and AS patients than the no-LTBI group, and 
the no-LTBI group had more inflammatory bowel disease patients than the LTBI group. Underlying comorbid-
ities did not differ significantly between the two groups. With regard to TNF antagonists, infliximab (29.6%), 
adalimumab (27.9%), golimumab (7.3%), and etanercept (11.7%) were administered, and 23.5% of the patients 
were treated with ≥2 TNF antagonists. Most patients (678; 96.6%) used other immunosuppressive drugs with 
the TNF antagonists. The median duration of TNF antagonist use was 15.5 months (range 0.5–114.8) and the 
median follow-up duration was 32.1 months (0.5–131.3). The LTBI group had a longer median duration of TNF 
antagonist use and a longer follow-up period than the no-LTBI group (TNF antagonists use duration, 18.6 vs. 12.7 
months; follow-up duration, 32.6 vs. 31.8 months, respectively) (Table 1).
Diagnosis and treatment of LTBI. Of the 702 patients, 168 (23.9%) had positive IGRA results. Of the total 
of 512 patients who underwent TSTs, 165 (32.2%) yielded positive results (data not shown). A total of 255 patients 
were diagnosed with LTBI before TNF antagonist use. Of these, 78 had both IGRA and TST positive results, 
whereas 177 were either IGRA positive (90 patients) or TST positive (87 patients) (Fig. 1). Among the patients 
who were IGRA negative but TST positive, 9 did not undergo LTBI treatment because their treating physician 
thought the results could be false positives due to Bacillus Calmette–Guérin (BCG) vaccination. Thus, with the 
exception of these 9 patients, 246 of the 255 (96.5%) received LTBI treatment. Table 2 shows the LTBI treatment 
regimens and outcomes. Two hundred and nineteen patients (89.0%) were treated with 9 months of daily isoni-
azid (9H), and 27 patients (11.0%) were treated with 3 months of daily isoniazid plus rifampicin (3HR). Median 
duration from LTBI treatment to starting TNF antagonist was 24 days (IQR, 21–35) and there was no statistical 
difference between 9H and 3HR groups (24 vs. 28 days). Of the total of 219 9H LTBI patients, 186 (84.9%) com-
pleted the treatment. Of those that did not, 9 stopped using the drug due to side effects, 20 were lost to follow-up, 
and 4 stopped the LTBI treatment because they also stopped TNF antagonist therapy. Of the patients treated with 
3HR, only 1 (3.7%) stopped the LTBI treatment due to side effects. Five patients developed active TB during the 
follow-up period, and all of them were in the 9H treatment group.
Clinical characteristics of 11 active TB patients. Table 3 shows clinical characteristics of the 11 active 
TB patients during or after TNF antagonist therapy. Five developed active TB during or after LTBI treatment, 
and of these, 3 exhibited isoniazid-resistant drug sensitivity. Six developed TB despite baseline negative LTBI 
screening results. Among the 11 active TB cases, 3 were extrapulmonary TB and the others were pulmonary and 
military TB. The mean duration of TNF antagonist use in the active TB patients was 9.9 months (range 0.7–31.5), 
and the mean duration from TNF antagonist initiation to TB onset was 20.7 months (range 2.0–73.2).
Incidence ratio of active TB after TNF antagonist therapy. Table 4 shows the observed numbers and 
SIR of active TB. In the LTBI group, 5/255 (1.96%) patients developed active TB associated with TNF antagonist 
therapy during the study period (897.60 patient-years of follow-up). Thus, the incidence of TB in TNF antagonist 
therapy with LTBI was estimated to be 557.04/100,000 patient-years. After adjustment for age and sex, the SIR 
was 6.01 (95% CI 1.94–14.04). In the baseline negative LTBI group before TNF antagonist therapy, 6/447 (1.34%) 
patients developed active TB during the study period (1336.53 patient-years follow-up). The incidence of TB in 
TNF antagonist therapy with initial negative LTBI was estimated to be 448.92/100,000 patient-years, and the SIR 
was 5.14 (95% CI 1.88–11.18).
Discussion
Previous studies have reported that TNF antagonist therapy increased the risk of active TB by approximately 
1.6–25.1 times1–3, 17–19. Recently, Navarra et al.11 suggested that the risk of developing TB with TNF antagonist 
LTBI treatment regimen
3 HR Total P9H
Number (%) 219/246 (89.0) 27/246 (11.0) 246
Completed treatment*, n (%) 186/219 (84.9) 26/27 (96.3) 212 (86.2) 0.142
Not completed, n (%) 33/219 (15.1) 1/27 (3.7) 34(13.8)
 side effects 9† 1‡ 9
 Dropout 20 0 20
 stop due to TNF antagonist stop 4 0 4
Duration from LTBI treatment to 
initiation of TNF antagonist, median 
(IQR), days
24 (21–35) 28 (14–90) 24 (21–35) 0.110
Active TB occurrence during follow up 5/219 (2.3) 0/27 (0) 5 NS
Table 2. Treatment regimens and outcomes for LTBI in 246 patients. Data are presented as numbers 
(percentages) unless otherwise indicated. *Completed Treatment was defined as the ingestion of >80% of 
all prescribed medications within 43 weeks for 9H or within 16 weeks for 3HR. †Five hepatitis, two active TB 
during LTBI treatment, one skin rash and one mood change. ‡One skin rash. LTBI, latent tuberculosis infection; 
H, isoniazid; HR, isoniazid plus rifampicin; TNF, tumor necrosis factor; TB, tuberculosis; NS, not significant.
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therapy is higher in Asia than in Western Europe and North America, due to a higher burden of TB incidence. 
In the current study, the SIR of active TB in patients treated with TNF antagonists was 6.01 in the LTBI group 
and 5.14 in the initial negative LTBI group. Our findings are comparable with those of a study conducted in 
another tertiary referral hospital in Korea20. However, according to a recent large cohort multicenter study in 873 
inflammatory bowel disease patients receiving TNF antagonists in Korea, the adjusted SIR was 41.7 compared 
with that of a age and sex matched sample of the general population21. Possible reasons for this discrepancy are 
differences in LTBI screening rates, screening methods, and rates of LTBI chemoprophylaxis. Most patients in 
the current study (808/823, 98.2%) were screened for LTBI prior to TNF antagonist therapy, and the screening 
methods used were IGRA with or without TST in accordance with Korean guidelines in immunocompromised 
patients. Furthermore, 246/255 (96.5%) patients diagnosed with LTBI received chemoprophylaxis. Conversely, 
the aforementioned large multicenter study21 reported that the overall LTBI screening rate was 81.6%, further-
more, 12.9% of patients were screened by only the TST, and 86.3% of LTBI patients received chemoprophylaxis. 
TNF antagonists are increasingly used to treat various inflammatory diseases in Korea. However, LTBI screening 
and its treatment before TNF antagonist therapy have not been performed completely depending on the physician 
and hospital, in the real world. The differences of standardized incidence of TB ratio between current study and 
the multicenter study described above21 emphasized the importance of proper screening prior to TNF antagonist 
therapy and LTBI treatment to reduce the incidence of active TB development.
There is insufficient evidence of the effectiveness of the different LTBI chemoprophylaxis regimens. In most 
countries, 9 months of treatment with isoniazid (9H) is currently recommended to prevent TB in LTBI, how-
ever, alternative regimens such as 3 months of treatment with isoniazid plus rifampicin (3HR) or 4 months of 
Case 1 2 3 4 5 6 7 8 9 10 11
Age/sex 47/M 50/F 55/M 27/M 57/F 20/F 79/F 55/M 56/F 33/M 49/M
Underlying 
disease CD RA CD AS RA CD RA CD RA CD RA
Anti-TNF 
agent used Ada + INF Ada INF Gol Eta + Ada INF Eta + Ada INF Ada + Eta INF INF
Baseline 
chest x-ray normal normal healed TB





0 29 15 10 11.5 ND 0 ND 0 0 0
Baseline 
IGRA Positive Positive Positive Positive Positive Negative Negative Negative Negative Negative Negative
LTBI Tx Yes Yes Yes Yes Yes No No No No No No
LTBI Tx 








21 31 21 43 34 — — — — — —
LTBI Tx 





10.7 13.1 1.4 1 23 20.6 31.5 3.3 3.3 1.2 0.7




30.9 34.9 2.9 3.4 23.5 21.9 73.2 4.2 28.8 2.4 2


























sensitivity all S INH-R INH-R INH-R all S all S all S all S all S all S all S
TB Tx 
outcomes completed completed completed completed death completed death completed completed completed completed
Table 3. Clinical characteristics of 11 active TB patients during or after TNF antagonists therapy. *Healed TB 
in chest radiography was defined as apical fibronodular lesions, calcified lymph nodes, calcified solitary nodules, 
and pleural thickening. TB, tuberculosis; TNF, tumor necrosis factor; CD, crohn’s disease; RA, rheumatoid 
arthritis; AS, ankylosing spondylitis; Ada, adalimumab; INF, infliximab; Gol, golimumab; Eta, etanercept; TST, 
tuberculin skin test; ND, not done; IGRA, interferon gamma release assay; LTBI Tx, latent tuberculosis infection 
treatment; H, isoniazid; EPTB, extrapulmonary TB; PTB, pulmonary TB; LN Bx, lymph node biopsy; all S, all 
sensitive; INH-R, isoniazid resistant.
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treatment with rifampicin (4R) have also been considered acceptable2. A study conducted in 2008, 92.6% of 
active TB patients in South Korea were sensitive to all anti-TB drugs and 7.4% of patients were resistant to one 
or more anti-TB drugs22 Another study in 2004 reported that 5% of TB patients were resistant to isoniazid at first 
treatment and 7% among retreatment patients23. Considering the lower rate of drug resistant active TB in South 
Korea, Korea guidelines still recommend 9H LTBI treatment regimen as a first line therapy. However, 4R and 3HR 
regimens are also accepted. In current study, 219/246 (89%) patients were treated with the 9H regimen, whereas 
27/246 (11%) were treated with the 3HR regimen. However, the chemoprophylaxis completion rates were 84.9% 
for 9H and 96.3% for 3HR. During follow-up, 5 patients developed TB despite chemoprophylaxis of LTBI and 
all of these patients were treated with the 9H regimen, though notably this difference in active TB incidence rate 
according to regimen was not statistically significant, due to the relatively small percentage of patients treated 
with 3HR. Three out of 5 patients were resistant to isoniazid. Possible reasons for those results were H resistant 
LTBI or developing H resistant active TB after 9H chemoprophylaxis. We cannot confirm the exact sequence of 
incidence, however, we have to consider special situation like exposure to H resistant TB patients before deciding 
LTBI regimen. Several studies have suggested that the 3HR or 4R regimens seem to be superior to the 9H regi-
men due to the relatively shorter course of treatment, high completion rate, and acceptable rate of adverse drug 
reactions13, 20, 24. That suggestion seems reasonable, especially in patients with low compliance, or in cases where 
there is an urgent need for TNF antagonists with a short induction period of chemoprophylaxis and a high risk 
of reactivating LTBI.
In this current study, 2 patients revealed healed TB lesion on chest x-ray with negative TST and IGRA result 
(Table 1). Although this 2 patients didn’t develop active TB without LTBI treatment, previous studies reported 
that healed TB lesion without anti-TB treatment history increased risk of developing active TB about 6–19 
times25, 26. Therefore many guidelines recommend LTBI treatment before anti-TNF therapy even though negative 
IGRA or TST result if patient’s chest x-ray had healed TB lesion without treatment history4–6. Among initial LTBI 
positive group, only 3.5% (9/255) patients have TB scars on x-ray (Table 1), but among active TB patients after 
LTBI treatment, 2 out of 5 (40%) patients have TB scars (Table 3). UK guideline recommends completion of LTBI 
treatment before anti-TNF therapy in patients with TB scars due to high risk of developing TB5. A study con-
ducted in South Korea suggested 3HR seemed to be superior to the 9H regimen especially in patients with high 
risk of reactivating LTBI20. In respect that patients with TB scars have increased risk of developing TB, it seems 
reasonable that 3HR prophylactic regimen is more appropriate rather than 9H mono-therapy.
In a previous study, the majority of cases of TB related to TNF antagonist therapy occurred close to the time 
of treatment initiation27. In the present study, of a total of 11 active TB patients, 5 (45.5%) developed active TB 
within 6 months of the initiation of TNF antagonist therapy, and 6 (54.5%) developed TB 20 months after the 
initiation of TNF antagonist therapy. This biphasic occurrence of active TB development has also been reported 
LTBI (+) Patients
Follow up 
duration (y) Patient-years Observed Expected* SIR 95% CI
Male 134 3.19 427.46 3 0.38 7.89 1.28–23.04
Female 121 3.89 470.69 2 0.32 6.16 0.69–22.23
Age (years)
  20–29 14 2.83 39.62 1 0.03
  30–39 40 2.97 118.8 0 0.08
  40–49 70 4.14 289.8 1 0.19
  50–59 62 3.39 210.18 3 0.18
  60–69 46 3.81 175.26 0 0.21
  70–79 23 2.82 64.86 0 0.15
  ≥80 0 0 0 0 0
Overall 255 3.52 897.60 5 0.71 6.01 1.94–14.04
No LTBI Patients Follow up duration (y) Patient-years Observed Expected* SIR 95% CI
Male 222 2.98 661.56 3 0.59 5.10 1.02–14.89
Female 225 3.00 675.00 3 0.47 6.44 1.29–18.82
Age (years)
  20–29 112 2.68 300.16 1 0.25
  30–39 121 2.87 347.27 1 0.23
  40–49 93 3.24 301.32 1 0.20
  50–59 58 3.41 197.78 2 0.17
  60–69 41 2.8 114.8 0 0.14
  70–79 18 3.17 57.06 1 0.13
  ≥80 4 4.69 18.76 0 0.06
Overall 447 2.99 1336.53 6 1.06 5.14 1.88–11.18
Table 4. The observed numbers and standardized incidence ratio of patients with active TB. *To estimate 
‘expected TB’ the sex and age specific TB patient notifications in 2011 were extrapolated from Korea centers for 
disease control and prevention. TB,tuberculosis; SIR, standardized incidence ratio; CI, confidence interval.
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in another study28. Possible reasons for these results include reactivation of LTBI in the early period of TNF antag-
onist therapy, and possible de novo infection with TB in the late period of long-term TNF therapy. In the current 
study, 6 patients developed active TB despite baseline negative LTBI. Among these patients, 3 developed TB 
within 6 months. Considering the short interval between the initiation of TNF antagonist therapy and the onset 
of active TB, the emergence of active TB in these patients may have been associated with false negative screening 
results29. With regard to overcoming this problem, several studies have suggested that IGRA and TST combina-
tion screening method is a safer, and more appropriate strategy for detecting LTBI in immune-mediated inflam-
matory disease, especially in high TB incidence30–32. The Korean Guidelines for Tuberculosis4 recommend either 
IGRA only or IGRA and TST in combination for screening for LTBI in immunocompromised patients. However, 
detecting LTBI with both IGRA and TST combination methods in patients at high risk of LTBI reactivation such 
as those undergoing TNF antagonist therapy may be worth considering. Of the 11 patients with newly developed 
TB in the current study, 6 developed TB 20 months after the initiation of TNF antagonist therapy. Among these, 
3 developed TB after LTBI treatment and 3 developed TB even though they showed negative results in LTBI 
screening. Although they could not recall close contact with active TB patients, it is possible that long-term TNF 
antagonist therapy may predispose patients to both de novo TB infection and reactivation of LTBI. To detect de 
novo TB infection, some experts have suggested that repeated testing for LTBI using IGRA may be considered in 
patients at ongoing risk of TB exposure (i.e., via travel, work, or by way of living in a high TB incidence country)33.
The current study has several limitations. It was conducted at only a single, tertiary hospital; hence the find-
ings are not representative of all patients undergoing TNF antagonist therapy in Korea. It is difficult to assess the 
risk factors for TB development, due to the relatively small number of active TB cases. LTBI and no LTBI groups 
are not exactly matched in clinical characteristics especially the duration of TNF antagonist use which could affect 
developing TB risk and acquiring LTBI. SIR methodology in the TB incidence also has a limitation because of not 
being corrected for the underlying disease. Furthermore, due to the retrospective nature of the study, accurate 
BCG vaccination histories and histories of close contact with active TB patients could not be obtained. Notably, 
the study also has several strengths. It provided information about baseline LTBI status before TNF antagonist 
therapy and the difference in TB incidence according to baseline screening results. Further predictive risk strati-
fication methods need to be investigated via multicenter, well-designed studies.
Conclusion
In the current study, the incidence of TB in patients treated with TNF antagonists increased even after LTBI treat-
ment, and also in patients who exhibited baseline negative LTBI screening results. During the first several months 
of TNF antagonist therapy, short regular follow-ups and close monitoring of signs and symptoms compatible with 
active TB is important due to the high risk of LTBI reactivation. Clinicians should also be aware of the risk of the 
development of active TB after several years, even after LTBI treatment and despite baseline negative LTBI screen-
ing results. Therefore, regular monitoring and serial tests need to be considered during long-term TNF antagonist 
therapy, to detect de novo TB infection, especially in intermediate to high TB burden countries.
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